Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Express Scripts
Johnson and Johnson
Merck
Colorcon

Last Updated: November 30, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MENINGOCOCCAL GROUP B VACCINE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for meningococcal group b vaccine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000820 ↗ A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 1969-12-31 PRIMARY: To examine the effect of aldesleukin ( IL-2 ) on viral activity in the blood. To determine the safety of low-dose IL-2 in combination with antiretroviral therapy versus antiretroviral therapy alone. SECONDARY: To examine delayed type hypersensitivity responses to skin test antigens and antibody responses to protein and polysaccharide vaccines. The profound immune impairment that results from HIV-1 infection is due, at least in part, to the loss of CD4+ T cells and the cytokines these cells secrete, especially IL-2 and interferon-gamma. Antiretroviral agents do not directly address the problem of immune impairment. Replacement of IL-2 at nontoxic doses may prevent or delay clinical immunosuppression and its attendant opportunistic infections. Also, since patients with HIV-1 infection respond suboptimally to routine protein and polysaccharide immunizations, IL-2 may provide an adjuvant effect on vaccine responses.
NCT00496015 ↗ Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A Completed GlaxoSmithKline Phase 3 2007-07-02 The purpose of this trial is to assess if the rate of febrile reactions following the co-administration of a booster dose of pneumococcal conjugate vaccines with standard infant vaccines is lowered when paracetamol is given prophylactically and to assess the impact of pneumococcal conjugate vaccine on pneumococcal and H. influenzae nasopharyngeal carriage compared to control group receiving meningococcal conjugate vaccine (GSK134612). This protocol posting deals with objectives & outcome measures of the booster phase. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00370318).
NCT00935883 ↗ Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) Completed Alexion Pharmaceuticals Phase 2 2009-07-01 To evaluate the safety and efficacy of eculizumab for the treatment of dry AMD as evaluated by the change in drusen volume and area of geographic atrophy.
NCT00935883 ↗ Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) Completed Philip J. Rosenfeld, MD, PhD Phase 2 2009-07-01 To evaluate the safety and efficacy of eculizumab for the treatment of dry AMD as evaluated by the change in drusen volume and area of geographic atrophy.
NCT00962624 ↗ Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults Completed Novartis Vaccines Phase 2 2010-07-01 The study involves the measurement of immune response to vaccination with three doses of a meningococcal B vaccine and a single dose of a meningococcal ACYW conjugate vaccine in healthy adults (Laboratory workers). The study will be completed at the Manchester Medical Microbiology Partnership in the UK and will enrol staff who may be at potential occupational exposure to meningococci. Blood samples will be taken before and after each vaccination and used to determine if the vaccines induce protective responses.
NCT00962624 ↗ Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults Completed Dr. Elizabeth Miller Phase 2 2010-07-01 The study involves the measurement of immune response to vaccination with three doses of a meningococcal B vaccine and a single dose of a meningococcal ACYW conjugate vaccine in healthy adults (Laboratory workers). The study will be completed at the Manchester Medical Microbiology Partnership in the UK and will enrol staff who may be at potential occupational exposure to meningococci. Blood samples will be taken before and after each vaccination and used to determine if the vaccines induce protective responses.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for meningococcal group b vaccine

Condition Name

Condition Name for meningococcal group b vaccine
Intervention Trials
Infections, Meningococcal 3
Meningitis, Meningococcal 2
HELLP Syndrome Second Trimester 1
Meningococcal Meningitis, Serogroup B 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for meningococcal group b vaccine
Intervention Trials
Meningitis 4
Meningococcal Infections 3
Meningitis, Meningococcal 3
Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for meningococcal group b vaccine

Trials by Country

Trials by Country for meningococcal group b vaccine
Location Trials
United States 52
Canada 5
United Kingdom 3
Czech Republic 2
France 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for meningococcal group b vaccine
Location Trials
California 4
Florida 4
Ohio 3
North Carolina 3
New York 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for meningococcal group b vaccine

Clinical Trial Phase

Clinical Trial Phase for meningococcal group b vaccine
Clinical Trial Phase Trials
Phase 4 2
Phase 3 6
Phase 2 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for meningococcal group b vaccine
Clinical Trial Phase Trials
Completed 11
Not yet recruiting 4
Recruiting 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for meningococcal group b vaccine

Sponsor Name

Sponsor Name for meningococcal group b vaccine
Sponsor Trials
GlaxoSmithKline 5
Alexion Pharmaceuticals 4
National Institute of Allergy and Infectious Diseases (NIAID) 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for meningococcal group b vaccine
Sponsor Trials
Industry 14
Other 12
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Merck
Medtronic
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.